



## Osteoporosis Management in Women with a Fracture (OMW) 2024

Medicare

### Measure Description

The percentage of female patients 67-85 years of age as of December 31, 2024 who suffered a fracture and who had either a bone mineral density test (BMD) or prescription for a drug to treat osteoporosis in the six months after the fracture.

The measurement intake period for this measure, which is used to capture the first fracture, is July 1, 2023-June 30, 2024.

### Required Exclusions

- Patients use hospice services or elect to use a hospice benefit any time during 2024
- Patients who received palliative care or who had an encounter for palliative care any time during July 1, 2023-December 31, 2024.
- Patients who passed away any time during 2024
- Patients who had a bone mineral density test during the 24 months prior to the fracture
- Patients who had osteoporosis therapy or a prescription to treat osteoporosis during the 12 months prior to the fracture

*Note: The following exclusions are closed by **claims only**.*

- Patients 67 years of age and older as of December 31, 2024 who meet either of the following: enrolled in an Institutional SNP (I-SNP) or residing in long-term care as identified by the LTI flag in the CMS Monthly File any time during 2024
- Patients 67-80 years of age and older as of December 31, 2024 with two frailty indications on different dates of service in 2024 and advanced illness diagnosis on at least two different dates of service or dispensed dementia medication during 2023 or 2024.
- Patients 81 years of age and older as of December 31, 2024 with two frailty indications on different dates of service during 2024.

### Documentation Tips

- **Use CPT and SNOMED codes** to lessen the administrative burden of manual chart reviews.
- Patient reported BMD tests are acceptable and can be retrieved via supplemental data. This information must be taken as part of the patient's history and must include the month and year of the test.
- If the fracture resulted in an inpatient stay, a BMD test or long acting osteoporosis therapy administered during the stay will close the care opportunity. Please have a copy within the outpatient medical record.
- Osteoporosis medication therapy is identified through pharmacy data; therefore, these medications must be filled using the member's Part D prescription drug benefit.

### Documentation Tips Continued...



- BMD reports located in the patient's outpatient medical record will close the care opportunity as long as the test was completed within the appropriate time frame.
- Fractures of finger, toe, face and skull are **not** included in this measure.

### Common Codes

#### CPT Codes- Bone Mineral Density Tests

**76977-** Ultrasound bone density peripheral site

**77078-** CT bone mineral density axial skeleton

**77080-** DXA axial skeleton

**77081-** DXA appendicular skeleton

**77085-** DXA axial skeleton, (hips, pelvis, spine) including vertebral fracture assessment

#### SNOWMED Codes- Bone Mineral Density Tests

22059005, 312681000, 385342005, 391057001, 391058006, 391059003, 391060008, 391061007, 391062000, 391063005, 391064004, 391065003, 391066002, 391069009, 391070005, 391071009, 391072002, 391073007, 391074001, 391076004, 391078003, 391079006, 391080009, 391081008, 391082001, 440083004, 440099005, 440100002, 449781000, 707218004, 4211000179102

#### HCPCS- Osteoporosis Medication Therapy

J0897, J1740, J3110, J3111, J3489

### Resources

HEDIS MY2024 Technical Specs Vol 2. Pg. 213-208